Silence Therapeutics' siRNA hits the mark in polycythemia vera
London-based biotech firm Silence Therapeutics (Nasdaq: SLN) said on Monday that lead candidate divesiran met the primary endpoint of the Phase II SANRECO trial in polycythemia vera (PV), a rare blood cancer in which the bone marrow overproduces red blood cells. Shares rose sharply on the news, touching a 52-week high.
The 36-week, randomized, placebo-controlled study enrolled 48 phlebotomy-dependent patients, who received divesiran 6 mg/kg subcutaneously either every six weeks or every 12 weeks. Some 88% of treated patients were classed as clinical responders, against 19% on placebo, a difference the company reported as highly statistically significant.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze